DGAP-News: STADA Arzneimittel AG / Key word(s): Tender Offer
AOK 11 tender round: STADA takes top active ingredients
05.02.2013 / 16:40
---------------------------------------------------------------------
AOK 11 tender round: STADA takes top active ingredients
Awards for omeprazole, risperidone, simvastatin and mirtazapine, among
others
Bad Vilbel, February 5, 2013 - Following 18 awards in the tenth tender
round of the Allgemeine Ortskrankenkasse (AOK) in the middle of January,
Germany's largest association of statutory health insurance organizations
has now once again selected STADA Group companies for six active
ingredients in 38 alloted areas. In the process, STADA sales companies were
awarded the four strongest active ingredients in terms of sales that were
up for tender: omeprazole, risperidone, simvastatin and mirtazapine. These
STADA products will now be available to the approximately 24 million
individuals insured by AOK.
'The tendered active ingredients that STADA won are among the most commonly
needed medicines in existence', says Hartmut Retzlaff, Chairman of the
Executive Board of STADA Arzneimittel AG. 'We are happy that we can make a
significant contribution to the supply of medicine and therefore to
people's health as the only independent generics Group in Germany. In
consideration of the challenging conditions of the German discount
agreement system, that does not go without saying.'
The public health insurance association tendered a total of eight active
ingredients each in eight alloted areas for three contract partners.
STADApharm was awarded eight alloted areas for mirtazapine and omeprazole,
five for risperidone, seven for simvastatin and one alloted area for the
active ingredient combination of lisinopril and hydrochlorothiazide. ALIUD
PHARMA was awarded eight areas for the active ingredient combination of
losartan and hydrochlorothiazide as well as one alloted area for
simvastatin. The contractual period starts on June 1, 2013.
About STADA Arzneimittel AG
STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad
Vilbel, Germany. STADA's business model focuses on the health care market.
At the center of the internationally oriented business activities are the
pharmaceutical and, in particular, the generics market with sustainable
growth potentials. As a globally leading generics producer, STADA has a
traditionally strong presence in Europe and is the clear number 3 in
Germany. In financial year 2011, STADA achieved Group sales of EUR 1,715.4
million, adjusted earnings before interest, taxes, depreciation and
amortization (EBITDA) of EUR 337.2 million and adjusted net income of EUR
146.6 million. As of June 30, 2012, STADA employed 7,867 people worldwide.
For more information, please contact:
STADA Arzneimittel AG
Corporate Communications
D-61118 Bad Vilbel
Tel.: +49(0) 6101 603-165
Fax: +49(0) 6101 603-506
e-mail: communications@stada.de
End of Corporate News
---------------------------------------------------------------------
05.02.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
StadastraÃe 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime
Standard); Freiverkehr in Berlin, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
200635 05.02.2013
DGAP-News: AOK 11 tender round: STADA takes top active ingredients
| Source: EQS Group AG